Thursday, May 21, 2009

AXENTIS and Key Executives Share First Hand Experiences at a Workshop on Corporate Integrity Agreements (CIAs) at CBI's Premiere Forum

Leaders from Medco and Purdue Pharma Join Workshop "Apply a CIA Implementation Plan to Enhance Compliance Programs

Cleveland, OH (Vocus/PRWEB ) May 21, 2009 -- AXENTIS, a leading provider of enterprise-wide governance, risk and compliance (GRC) management solutions, announced a pre-conference workshop on using technology to expedite a Corporate Integrity Agreement (CIA). These agreements require companies to ramp up their compliance programs under tight deadlines or face stiff fines and other penalties from regulatory bodies. Workshop leaders Gary M. Fingerhut, Senior Vice President and Leila A. Daiuto, Director, Life Sciences & Healthcare will be joined by executives from Medco and Purdue Pharma who will share firsthand experiences and outline best practices.

What: Pre-Conference Workshop: "Apply a CIA Implementation Plan to Enhance Compliance Programs"
When: June 17, 2009, 8:30 a.m. to 12:00 p.m.
Where: Westin Arlington Gateway in Arlington, VA
Workshop Leaders: Daniel C. Walden, Senior Vice President - Compliance and Chief
Privacy Officer, Medco Health Solutions, Inc.
Christopher J. Santarcangelo, Assistant Director of Corporate
Compliance, Purdue Pharma L.P.
Gary M. Fingerhut, Senior Vice President, AXENTIS
Leila A. Daiuto, Director, Life Sciences & Healthcare, AXENTIS

Apply a CIA Implementation Plan to Enhance Compliance Programs
Details: This workshop brings together senior-level executives from across
life science organizations that have been directly involved in a CIA or DPA settlement and want to share their first-hand experiences. It offers the opportunity to glean peer experiences, including specific strategies for training, monitoring, auditing, and developing remediation plans. The White Paper: Meeting the CIA Challenge: Critical Technology Enablers for Immediate and Long-Term Compliance will be distributed at the event.

About CBI's Premiere Forum on Bio/Pharmaceutical and Medical Device Corporate Integrity Agreements (CIAs), June 17-18, 2009:

Government prosecutors have publicly announced their continued    resolve to investigate and bring charges against pharmaceutical, biotech and medical device companies who participate in alleged misconduct. The financial and reputational repercussions associated with non-compliance have never been higher. Many times, these settlements also bring with them a Corporate Integrity Agreement or other integrity obligation. Operating under the strict oversight of such agreements brings a great burden to your compliance departments. The event promises to attract compliance, legal and other professionals from a vast array of companies and functions. Not only will you receive up-to-date information about    the current regulatory and legal landscape, but there will also be discussion of what can be learned from specific enforcement actions and settlements. For more information, please visit www.cbinet.com/cia.


About AXENTIS
AXENTIS is a global leader of governance, risk and compliance (GRC) management solutions for highly regulated industries including life sciences, healthcare, financial services, energy, utilities, manufacturing, and others. AXENTIS' risk-driven compliance approach helps organizations to effectively and consistently address internal and external risks associated with all legal, regulatory, and corporate mandates and policies with which they must comply including established federal government standards for an effective compliance program. Founded in 1999, AXENTIS reaches individuals worldwide via a Software-as-a-Service (SaaS) model. For more information, please visit http://www.axentis.com.

Media Contact:
Sandra Leon
AXENTIS
216.896.8416

See Also:

[Via Legal / Law]

Posted by prolink at 10:45 AM

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)